Achieve Life Sciences (ACHV) Price & Analysis

Compare

1,731 Followers

ACHV Stock Chart & Stats

$5.66

-$0.11(-3.08%)

At close: Jan 08 4:00 PM EST

$5.66

-$0.11(-3.08%)

Day’s Range― - ―

52-Week Range$1.84 - $5.78

Previous CloseN/A

Volume131.37K

Average Volume (3M)574.00K

Market Cap

$295.98M

Enterprise Value$122.55M

Total Cash (Recent Filing)$48.11M

Total Debt (Recent Filing)$9.96M

Price to Earnings (P/E)―

Beta1.92

Next Earnings

Mar 12, 2026

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding53,233,990

10 Day Avg. Volume740,984

30 Day Avg. Volume574,000

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)5.40

Price to Sales (P/S)0.00

P/FCF Ratio-3.79

Enterprise Value/Market Cap0.41

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.05K

Enterprise Value/Ebitda-2.39

Forecast

1Y Price Target

$15.33

Price Target Upside170.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And SafetyConsistent positive outcomes from ORCA-2 and ORCA-3 trials, along with decades of international use, support a favorable efficacy and safety profile that strengthens the case for approval and clinician confidence.

First-to-market Commercial OpportunityPotential to be the first approved prescription therapy for nicotine vaping cessation and targeted label expansion could enable meaningful penetration of an underserved cessation market with focused promotion.

Regulatory AccelerationAward of an FDA Commissioner's National Priority Voucher combined with Breakthrough Therapy designation could accelerate review interactions and shorten the path to approval for a vaping cessation indication.

Bears Say

Dependence On External PartnerRequirement to secure a commercialization partner for broader market rollout could reduce future revenue share and introduce execution delays if partnership terms or timelines are protracted.

Financing RiskNeed for additional capital could lead to fundraising that dilutes existing shareholders or delays investment in manufacturing and commercialization plans.

Achieve Life Sciences News

Achieve Life Sciences confirms promotion of Mark Rubinstein to CMO

Achieve Life Sciences (ACHV) announced that it has confirmed the promotion of Mark Rubinstein, M.D., from Interim Chief...

2d ago

ACHV

H.C. Wainwright names two best 2026 ideas in SMID-cap biopharma

H.C. Wainwright named Achieve Life Sciences (ACHV) and Connect Biopharma (CNTB) the firm’s two best ideas for 2026...

9d ago

ACHV

CNTB

Achieve Life near FDA approval of smoking addiction treatment, Hunterbrook says

Achieve Life Sciences (ACHV) is close to gaining FDA approval of cytisinicline as a safe, effective treatment for...

15d ago

ACHV

Achieve Life Sciences initiated with an Outperform at Citizens JMP

Citizens JMP analyst Jason Butler initiated coverage of Achieve Life Sciences (ACHV) with an Outperform rating and $19...

2M ago

ACHV

Promising Developments and Strategic Advancements Drive Positive Outlook for Achieve Life Sciences

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Achieve Life Sciences. The associated price...

2M ago

ACHV

Positive Outlook for Achieve Life Sciences: Buy Rating Backed by Promising Regulatory Progress and Market Potential

JonesTrading analyst Justin Walsh has reiterated their bullish stance on ACHV stock, giving a Buy rating yesterday. Justin...

2M ago

ACHV

Achieve Life Sciences Reports Q3 2025 Results

Achieve Life Sciences ( ($ACHV) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

ACHV

Achieve Life Sciences: Key Insights from Earnings Call

Achieve Life Sciences (($ACHV)) has held its Q3 earnings call. Read on for the main highlights of the...

2M ago

ACHV

Achieve Life Sciences: Advancements in Cytisinicline Propel Buy Rating Amid Regulatory Milestones and Clinical Success

H.C. Wainwright analyst Brandon Folkes has reiterated their bullish stance on ACHV stock, giving a Buy rating on...

2M ago

ACHV

Achieve Life Sciences reports Q3 EPS (28c), consensus (26c)

“The FDA’s acceptance of our NDA for cytisinicline in smoking cessation is an important milestone for Achieve, reflecting...

2M ago

ACHV

ACHV Earnings this Week: How Will it Perform?

Achieve Life Sciences (ACHV) is scheduled to report 3rd quarter earnings on 11/06/2025, before the market opens. Regarding...

2M ago

ACHV

Achieve Life Sciences announces several milestones in its ORCA-OL trial

Achieve Life Sciences (ACHV) announced several milestones in its ORCA-OL long-term safety trial supporting the New Drug Application,...

2M ago

ACHV

Achieve Life Sciences appoints Atkisson as Chief Legal Officer

Achieve Life Sciences (ACHV) announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role,...

3M ago

ACHV

Morning Movers: Regional banks in focus after reporting Q3 results

Stock futures are mixed in early trading amid growing concerns over regional banks’ exposure to bad loans and...

3M ago

AXP

ACHV FAQ

What was Achieve Life Sciences Inc’s price range in the past 12 months?

Achieve Life Sciences Inc lowest stock price was $1.84 and its highest was $5.78 in the past 12 months.

What is Achieve Life Sciences Inc’s market cap?

Achieve Life Sciences Inc’s market cap is $295.98M.

When is Achieve Life Sciences Inc’s upcoming earnings report date?

Achieve Life Sciences Inc’s upcoming earnings report date is Mar 12, 2026 which is in 57 days.

How were Achieve Life Sciences Inc’s earnings last quarter?

Achieve Life Sciences Inc released its earnings results on Nov 06, 2025. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.244 by -$0.036.

Is Achieve Life Sciences Inc overvalued?

According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Achieve Life Sciences Inc pay dividends?

Achieve Life Sciences Inc does not currently pay dividends.

What is Achieve Life Sciences Inc’s EPS estimate?

Achieve Life Sciences Inc’s EPS estimate is -0.29.

How many shares outstanding does Achieve Life Sciences Inc have?

Achieve Life Sciences Inc has 53,233,990 shares outstanding.

What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?

Achieve Life Sciences Inc reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.244. Following the earnings report the stock price went down -3.854%.

Which hedge fund is a major shareholder of Achieve Life Sciences Inc?

Currently, no hedge funds are holding shares in ACHV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Achieve Life Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-161.08%

Trailing 12-Months

Asset Growth

8.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Achieve Life Sciences (ACHV) Earnings & Revenues

Historic Earnings Reports

ACHV Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant regulatory achievements and strategic advancements, particularly in gaining an expedited review for vaping cessation. However, funding needs for further clinical trials and challenges in aligning commercial strategies for two different market entries pose potential risks.View all ACHV earnings summaries

ACHV Stock 12 Month Forecast

Average Price Target

$15.33

▲(170.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,6.126153846153846,7.282307692307692,8.438461538461539,9.594615384615384,10.750769230769231,11.906923076923078,13.063076923076924,14.21923076923077,15.375384615384615,16.531538461538464,17.68769230769231,18.843846153846155,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.766923076923076,6.563846153846153,7.360769230769231,8.157692307692308,8.954615384615384,9.75153846153846,10.548461538461538,11.345384615384614,12.142307692307693,12.939230769230768,13.736153846153844,14.533076923076923,{"y":15.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.356923076923077,5.743846153846153,6.13076923076923,6.5176923076923075,6.904615384615385,7.291538461538462,7.678461538461538,8.065384615384616,8.452307692307691,8.839230769230769,9.226153846153846,9.613076923076923,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.97,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >